PTC Therapeutics Reports Strong Year-End Results and Corporate Update
On February 19, 2026, PTC Therapeutics, Inc. (NASDAQ: PTCT) released its corporate update along with its financial results for the fourth quarter and full year ending December 31, 2025. The report showcased the company’s robust performance, driven largely by the successful launch of its innovative treatment, Sephience.
1. Key Corporate Highlights
PTC Therapeutics reported impressive achievements throughout 2025, underlining its strong commercial engine and innovative research and development (R&D) programs.
- Revenue Performance: The company achieved full-year product and royalty revenue of $831 million, surpassing earlier guidance.
- Sephience Launch: The global launch of Sephience has begun positively, generating $111 million in total net revenue since its launch, with Q4 2025 revenues alone amounting to $92 million. This includes a substantial $81 million from the U.S. market and $11 million from international markets.
- Patient Reach: As of December 31, 2025, 946 patients worldwide were receiving commercial therapy with Sephience, and PTC has received 1,134 patient start forms in the U.S.
- Expanding Global Footprint: With recent approvals in Japan and Brazil, the global footprint of Sephience is expected to expand to between 20 to 30 countries by the end of 2026.
- Royalty Asset Sale: In December 2025, PTC sold its remaining Evrysdi® (risdiplam) royalty to Royalty Pharma for $240 million upfront, with potential milestones of $60 million based on sales performance. PTC also retains a significant $150 million milestone from Roche, contingent on Evrysdi sales reaching $2.5 billion in a single year.
- Advancements in R&D: PTC conducted an End-of-Phase 2 meeting with the FDA to discuss its votoplam program for Huntington's disease, reaching an alignment on the design for a global Phase 3 trial slated to begin in the first half of 2026. Additionally, a Type C meeting regarding the vatiquinone program for Friedreich's ataxia indicated that further studies would be required for NDA resubmission.
2. Financial Highlights for Q4 and Full Year 2025
Revenue Breakdown:
- Total Revenues: PTC reported total revenues of $164.7 million for Q4 2025, down from $213.2 million in Q4 2024, while full-year revenues surged to $1.73 billion, compared to $806.8 million in 2024.
- Product Revenues: Total net product revenues for Q4 2025 were $184.0 million, up from $150.1 million year-over-year. Full-year product revenues were $586.7 million, a slight increase from $582.1 million in 2024.
Product Performance:
- Translarna™ (ataluren): Q4 2025 revenues dipped to $39.0 million from $89.1 million in Q4 2024, with full-year revenues declining to $235.3 million, compared to $321.1 million in the previous year.
- Emflaza® (deflazacort): Q4 revenues fell to $27.1 million from $50.5 million in Q4 2024, with full-year revenues also decreasing to $146.4 million from $207.2 million.
- Evrysdi Royalties: Roche reported Evrysdi sales of approximately 1,757 million CHF for 2025, yielding royalty revenue of $244.2 million for PTC, up from $203.9 million in 2024.
Expense Overview:
- R&D Expenses: GAAP R&D expenses for Q4 2025 were $133.1 million, compared to $124.8 million in Q4 2024, while full-year expenses were $455.2 million, down from $534.5 million.
- SG&A Expenses: GAAP SG&A expenses rose to $96.9 million for Q4 2025, from $84.7 million in Q4 2024, with full-year expenses totaling $347.1 million, compared to $300.9 million in the prior year.
Net Income/Loss:
- PTC reported a net loss of $135.0 million for Q4 2025, compared to a loss of $65.9 million for the same quarter in 2024. However, the company achieved a net income of $682.6 million for the full year, rebounding from a loss of $363.3 million in 2024.
Cash Position:
- As of December 31, 2025, PTC held cash, cash equivalents, and marketable securities amounting to $1.945 billion, significantly up from $1.139 billion at the end of 2024.
3. Guidance for Full Year 2026
Looking ahead, PTC Therapeutics has set its sights on total product revenue of $700 to $800 million for 2026, representing a growth of 19% to 36% from 2025, primarily driven by Sephience. The company anticipates GAAP R&D and SG&A expenses in the range of $775 to $815 million, while non-GAAP expenses are estimated at $680 to $720 million, excluding approximately $95 million in non-cash, stock-based compensation expenses.
4. Conclusion
PTC Therapeutics has demonstrated its resilience and growth potential in a competitive biopharmaceutical landscape, with the successful launch of Sephience and strategic advancements in its R&D pipeline. As the company transitions into 2026, stakeholders remain optimistic about its trajectory towards cash flow breakeven and sustained revenue growth.
